Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Talon Compounding Pharmacy
WARNING LETTER
•Talon Compounding Pharmacy•June 29, 2016

Talon Compounding Pharmacy – FDA Warning Letter, Jun 29, 2016

Record Details

An FDA inspection of Talon Compounding Pharmacy from June 21-29, 2016, revealed serious deficiencies in sterile drug product production and failure to meet Section 503A of the FDCA. The firm voluntarily recalled HCG and sermorelin due to sterility assurance issues.

Violations included compounding without valid patient-specific prescriptions and using bulk drug substances (b)(4) not eligible for 503A exemptions, rendering products unapproved new drugs and misbranded. Insanitary conditions observed included: transferring sterile products into less than ISO 5 air, inadequate cleanroom separation and sealing, improper aseptic technique by operators (e.g., touching gloved hands with bare hands, blocking airflow), using expired disinfectants, lack of sterilization/depyrogenation for glassware, and improper storage of sterile vials.

The FDA cited violations of FDCA sections 501(a)(2)(A) (adulterated drugs due to insanitary conditions), 505(a) and 301(d) (unapproved new drugs), and 502(f)(1) (misbranded drugs due to inadequate directions for use).

While some corrective actions were acknowledged, many were deemed inadequate or lacked sufficient documentation, such as protocols for protecting sterile products during transfer, detailed smoke study reports, and adequate disinfection frequencies. The FDA emphasized the need for a comprehensive assessment of operations, potentially with a third-party

Company
Talon Compounding Pharmacy
Inspection date
June 29, 2016
Product type
Drugs
Office
Dallas District Office
People
  • Monica R. Maxwell (Program Division Director)
  • Gay Dodson
  • Karen Tannert
View Company Profile

ID · 56d4d2d8-1a44-459c-b957-e17d69ba1336

Violation Codes10
21 U.S.C. 353a21 U.S.C. 352(f)(1)21.U.S.C. 355(a)21 U.S.C. 351(a)(2)(A)21 U.S.C. 331(k)21 U.S.C. 331(d)21 CFR 21021 CFR 211FD&C Act 505FD&C Act 502(f)(1)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Talon Compounding Pharmacy
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.